Derivative exercise or conversion — not an open-market buy.
Traded Jan 12, 2026 · Filed Jan 13, 2026
Bruker's EXEC VP&PRES BRUKER NANO INC. sold $385K of Bruker shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$385,000
Shares × reported transaction price
on the day of results (Jan 12, 2026), 31 days before results of Feb 12, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +5.7% | −0.7% | +6.4% |
| 30 days | −25.7% | −1.3% | −24.4% |
| 90 days | −18.8% | +0.6% | −19.4% |
| 180 days | +20.0% | +8.5% | +11.5% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.